FY2018 EPS Estimates for Juno Therapeutics Inc (JUNO) Decreased by FBR & Co
Juno Therapeutics Inc (NASDAQ:JUNO) – FBR & Co reduced their FY2018 earnings per share estimates for Juno Therapeutics in a research note issued on Wednesday. FBR & Co analyst E. White now expects that the brokerage will post earnings per share of ($3.48) for the year, down from their prior forecast of ($3.28). FBR & Co has a “Market Perform” rating and a $30.00 price target on the stock.
Other equities analysts have also recently issued research reports about the company. Maxim Group cut their price target on Juno Therapeutics from $50.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, November 23rd. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target for the company. in a report on Monday, August 22nd. Standpoint Research assumed coverage on Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 price target for the company. Zacks Investment Research raised Juno Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th. Finally, SunTrust Banks Inc. lowered Juno Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $48.00 to $25.00 in a research note on Friday. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.40.
Juno Therapeutics (NASDAQ:JUNO) traded down 4.48% during trading on Monday, hitting $21.13. The stock had a trading volume of 2,250,119 shares. The stock’s market cap is $2.17 billion. Juno Therapeutics has a 12 month low of $19.41 and a 12 month high of $57.82. The stock has a 50 day moving average price of $27.32 and a 200-day moving average price of $32.73.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The firm earned $20.80 million during the quarter, compared to analysts’ expectations of $10.98 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. The business’s revenue for the quarter was up 1200.0% on a year-over-year basis.
A number of institutional investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. boosted its position in Juno Therapeutics by 40.8% in the third quarter. D.A. Davidson & CO. now owns 16,918 shares of the biopharmaceutical company’s stock worth $507,000 after buying an additional 4,900 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 98 shares during the last quarter. Credit Suisse AG boosted its position in Juno Therapeutics by 51.1% in the third quarter. Credit Suisse AG now owns 187,262 shares of the biopharmaceutical company’s stock worth $5,621,000 after buying an additional 63,346 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new position in Juno Therapeutics during the third quarter worth $2,401,000. Finally, Bamco Inc. NY boosted its position in Juno Therapeutics by 340.8% in the third quarter. Bamco Inc. NY now owns 443,107 shares of the biopharmaceutical company’s stock worth $13,298,000 after buying an additional 342,582 shares during the last quarter.
In other news, CEO Hans Edgar Bishop sold 84,035 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total value of $2,544,579.80. Following the completion of the transaction, the chief executive officer now owns 2,518,537 shares of the company’s stock, valued at approximately $76,261,300.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Robert Azelby sold 12,921 shares of the business’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the completion of the transaction, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.